Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On January 9, 2023, Biotech Acquisition Company (the "Company") received written
notice (the "Notice") from the Listing Qualifications Department of The Nasdaq
Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance
with Nasdaq Listing Rule 5620(a), due to the Company's failure to hold an annual
meeting of shareholders for the fiscal year ended December 31, 2021. The Notice
is only a notification of deficiency, not of imminent delisting, and has no
current effect on the listing or trading of the Company's securities on the
Nasdaq Capital Market.
The Notice states that the Company has until February 23, 2023 to submit a plan
to regain compliance with Listing Rule 5620(a). The Company intends to submit a
plan to regain compliance with Listing Rule 5620(a) within the required
timeframe. If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an
extension of up to 180 calendar days from the fiscal year end, or until June 29,
2023, to evidence compliance with Listing Rule 5620(a). If Nasdaq does not
accept the Company's plan, the Company will have the opportunity to appeal the
decision in front of a Nasdaq Hearings Panel.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data File
1
© Edgar Online, source Glimpses